Hutchmed (China)
HCM
Enerpac Tool
EPAC
Ermenegildo Zegna NV
ZGN
Lantheus
LNTH
eBay
EBAY
US Stock MarketDetailed Quotes
CELU Celularity
- 1.4500
- -0.1500-9.38%
Close Feb 25 16:00 ET
- 1.5300
- +0.0800+5.52%
Post 20:01 ET
34.52MMarket Cap-1.20P/E (TTM)
1.6400High1.4100Low345.21KVolume1.5900Open1.6000Pre Close515.24KTurnover3.07%Turnover RatioLossP/E (Static)23.81MShares7.970052wk High2.00P/B16.32MFloat Cap1.300052wk Low--Dividend TTM11.25MShs Float134.0000Historical High--Div YieldTTM14.38%Amplitude1.3000Historical Low1.4920Avg Price1Lot Size
Celularity Stock Forum
Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products
Tuesday, 25th February at 8:00 am
FLORHAM PARK, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced that on December 19, 2024, it received recommendation letters from the US Food and Drug Administration, or FDA, Tissue Reference Group, o...
1 min ago
Celularity Receives FDA Tissue Reference Group Recommendation Letters for Its Natalin and Acelagraft™ Wound Care Products
Can This New Cell Therapy Manufacturing Deal Transform Celularity's Revenue Potential?
Celularity Enters Strategic Collaboration Agreement With Clinical Stage Cell Therapy Company
I took a position here earlier solely based on the chart and today’s activity. It's giving that run vibe 🏃♀️
👀
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter
Tuesday, 10th December at 8:00 am
FLORHAM PARK, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced that it has received a letter from the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq"), confirming that Celularity has regained compliance with Nasdaq Listing ...
$Roth CH Acquisition V Co(Delisted) (ROCL.US)$ Ticker change tomorr...
Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023
Friday, 6th December at 8:00 am
• Celularity filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024, and is now current with its quarterly report filings
• Reported Total Net Revenue for the Three Months and the Nine Months ending September 30, 2024, are consistent with last guidance, with significant growth over the same perio...
No comment yet